Upregulation of HER-2/neu by Ovarian Ablation: Results of a Randomized Trial Comparing Leuprorelin to CMF as Adjuvant Therapy in Node-positive Breast Cancer Patients

By Lüftner D.  

Breast Cancer Research and Treatment, Vol. 80, Iss. 3, 2003-08 ,pp. : 245-255

Springer Publishing Company

Access to resources Recommend Favorite

Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients - a prospective, comparative, non-randomised study

By Fiets W.E.   van Helvoirt R.P.   Nortier J.W.R.   van der Tweel I.   Struikmans H.  

European Journal of Cancer, Vol. 39, Iss. 8, 2003-05 ,pp. : 1081-1088

Elsevier

Access to resources Recommend Favorite

HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer

By Konecny G.  

Breast Cancer Research and Treatment, Vol. 69, Iss. 1, 2001-09 ,pp. : 53-63

Springer Publishing Company

Access to resources Recommend Favorite

Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact?

By Kumar N.B.  

Breast Cancer Research and Treatment, Vol. 44, Iss. 2, 1997-06 ,pp. : 135-143

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer

By Fountzilas George   Pectasides Dimitrios   Christodoulou Christos   Timotheadou Eleni   Economopoulos Theofanis   Papakostas Pavlos   Papadimitriou Christos   Gogas Helen   Efstratiou Ioannis   Skarlos Dimosthenis  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 479-488

Humana Press, Inc

Access to resources Recommend Favorite